XML 36 R23.htm IDEA: XBRL DOCUMENT v3.25.3

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash and Cash Equivalents

The following is a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash on the unaudited condensed consolidated statements of cash flows:

In millions			September 30, 2025						December 31, 2024
Cash and cash equivalents			$	9,098					$	8,586
Restricted cash (included in other current assets)			57						95
Restricted cash (included in other assets)			197						203
Total cash, cash equivalents and restricted cash in the statements of cash flows			$	9,352					$	8,884

Schedule of Accounts Receivable, Net

Accounts receivable, net at September 30, 2025 and December 31, 2024 was composed of the following:

In millions			September 30, 2025						December 31, 2024
Trade receivables			$	11,221					$	9,881
Vendor and manufacturer receivables			17,779						13,891
Premium receivables			4,878						4,731
Other receivables			9,979						7,966
Total accounts receivable, net			$	43,857					$	36,469

Rollforward of Deferred Acquisition Costs

The following is a roll forward of deferred acquisition costs for the nine months ended September 30, 2025 and 2024:

									Nine Months Ended September 30,
In millions															2025						2024
Deferred acquisition costs, beginning of the period															$	1,747					$	1,502
Capitalization															389						405
Amortization expense															(255)						(217)
Deferred acquisition costs, end of the period															$	1,881					$	1,690

Schedule of Disaggregation of Revenue

The following tables disaggregate the Company’s revenue by major source in each segment for the three and nine months ended September 30, 2025 and 2024:

In millions			Health Care Benefits						Health Services						Pharmacy & Consumer Wellness						Corporate/ Other						Intersegment Eliminations						Consolidated Totals
Three Months Ended September 30, 2025
Major goods/services lines:
Pharmacy			$	—					$	46,800					$	30,428					$	—					$	(17,680)					$	59,548
Front Store			—						—						5,192						—						—						5,192
Premiums			33,739						—						—						11						(31)						33,719
Net investment income (loss)			513						(1)						—						120						—						632
Other			1,741						2,467						594						2						(1,024)						3,780
Total			$	35,993					$	49,266					$	36,214					$	133					$	(18,735)					$	102,871
Health Services distribution channel:
Pharmacy network (1)									$	26,408
Mail & specialty (2)									20,392
Net investment income (loss)									(1)
Other									2,467
Total									$	49,266
Three Months Ended September 30, 2024
Major goods/services lines:
Pharmacy			$	—					$	41,350					$	26,666					$	—					$	(13,357)					$	54,659
Front Store			—						—						5,196						—						—						5,196
Premiums			30,914						—						—						11						—						30,925
Net investment income (loss)			423						(1)						—						128						—						550
Other			1,659						2,780						561						3						(905)						4,098
Total			$	32,996					$	44,129					$	32,423					$	142					$	(14,262)					$	95,428
Health Services distribution channel:
Pharmacy network (1)									$	24,136
Mail & specialty (2)									17,214
Net investment income (loss)									(1)
Other									2,780
Total									$	44,129

In millions			Health Care Benefits						Health Services						Pharmacy & Consumer Wellness						Corporate/ Other						Intersegment Eliminations						Consolidated Totals
Nine Months Ended September 30, 2025
Major goods/services lines:
Pharmacy			$	—					$	132,258					$	84,135					$	—					$	(48,989)					$	167,404
Front Store			—						—						15,803						—						—						15,803
Premiums			100,731						—						—						34						(31)						100,734
Net investment income			1,307						10						—						322						—						1,639
Other			5,023						6,913						1,769						6						(2,917)						10,794
Total			$	107,061					$	139,181					$	101,707					$	362					$	(51,937)					$	296,374
Health Services distribution channel:
Pharmacy network (1)									$	74,187
Mail & specialty (2)									58,071
Net investment income									10
Other									6,913
Total									$	139,181
Nine Months Ended September 30, 2024
Major goods/services lines:
Pharmacy			$	—					$	118,575					$	73,463					$	—					$	(38,002)					$	154,036
Front Store			—						—						15,847						—						—						15,847
Premiums			91,947						—						—						36						—						91,983
Net investment income (loss)			1,076						(3)						—						325						—						1,398
Other			4,684						8,013						1,676						7						(2,545)						11,835
Total			$	97,707					$	126,585					$	90,986					$	368					$	(40,547)					$	275,099
Health Services distribution channel:
Pharmacy network (1)									$	66,448
Mail & specialty (2)									52,127
Net investment income (loss)									(3)
Other									8,013
Total									$	126,585

_____________________________________________

(1)Health Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including pharmacies owned by the Company, as well as activity associated with Maintenance Choice®, which permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.

(2)Health Services mail & specialty is defined as specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as mail order and specialty claims fulfilled by the Pharmacy & Consumer Wellness segment.

Schedule of Receivables and Contract Liabilities from Contracts with Customers

The following table provides information about receivables and contract liabilities from contracts with customers:

In millions			September 30, 2025						December 31, 2024
Trade receivables (included in accounts receivable, net)			$	11,221					$	9,881
Contract liabilities (included in accrued expenses and other current liabilities)			58						144

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the movement in deferred policy acquisition costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479401/944-30-55-2

+ Details

Name:	us-gaap_DeferredPolicyAcquisitionCostsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of supplemental cash flow information for the periods presented.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration